The Retinal Disorder Treatment Market is expected to register a CAGR of 9.11% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Product Type (Gels, Eye Solutions, Capsules and Tablets, Eye drops, Ointments); Disease Indication (Diabetic Retinopathy, Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Others), and Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Retinal Disorder Treatment Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Retinal Disorder Treatment Market Segmentation
Product Type- Gels
- Eye Solutions
- Capsules and Tablets
- Eye drops
- Ointments
- Diabetic Retinopathy
- Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Strategic Insights
Retinal Disorder Treatment Market Growth Drivers- Increasing Prevalence of Retinal Disorders: The rising prevalence of retinal disorders such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion is a major driver of growth in the retinal disorder treatment market. More people develop retinal disorders because diabetes affects more people and the worldwide population ages. Market researchers expect retinal disorder treatment sales to double because more people develop these eye conditions every year. People now understand the value of catching retinal disorders early so they need better treatment methods. Patients want treatments to protect their sight which makes the market expand. Healthcare experts and medicine manufacturers now work together to create advanced medical treatments like anti-VEGF drugs and laser treatments alongside corticosteroids to help patients with retinal conditions. When effective new retinal treatments enter the market they will help the treatment market grow bigger. The rising burden of retinal disorders and their impact on quality of life underscores the need for continued innovation and investment in retinal treatment options.
- Increased Focus on Early Detection and Diagnosis: More patients seek retinal disorder treatment because doctors now detect these diseases sooner. Early treatment of retinal diseases starts to manage the conditions before they cause vision loss and leads to better medical results. New diagnostic tools including OCT imaging and fluorescein angiography let doctors find retinal problems sooner so they can start treatment promptly. Market analysts expect the retinal disorder treatment market to expand rapidly because more effective diagnostic tools are being developed and distributed. More people are learning about the need for eye exams which helps doctors find retinal problems earlier. Identifying retinal issues early saves healthcare systems money because effective treatments at this point reduce the need for more advanced medical procedures. With more people opting for regular eye checkups, the demand for retinal treatments will continue to increase, driving market expansion.
- Advancements in Retinal Disease Treatment Technologies: The market for retinal disorder treatment grows because new medical technology helps doctors treat these diseases better. Advancements like gene therapies retinal implants and controlled drug delivery systems now improve how doctors treat retinal diseases. These technologies help doctors treat AMD and other retinal conditions better while making treatments work better and safer for patients. Anti-VEGF treatment helps patients with retinal problems by blocking blood vessel growth which doctors use to treat wet AMD and diabetic macular edema patients. Market analysts expect the retinal disorder treatment market to grow further because healthcare providers will use advanced medical tools more frequently. Combination therapies made from multiple treatment methods help doctors deliver better results. The market continues to grow because researchers and scientists keep developing better solutions for retinal disorders. The market share of advanced retinal therapies will expand because new treatments provide better results at individual patient levels.
- Growing Use of Anti-VEGF Therapies: One of the most significant trends in the retinal disorder treatment market is the growing use of anti-VEGF therapies. The retinal disorder treatment market now features anti-VEGF therapies as its main growth pattern. Doctors use anti-VEGF drugs (ranibizumab, aflibercept and bevacizumab) to treat retinal conditions especially wet AMD, diabetic macular edema and retinal vein occlusions. These treatments stop VEGF from activating in the retina which causes abnormal blood vessel growth. Research shows the anti-VEGF industry will expand further since doctors and patients accept these treatments more often while medical scientists create new anti-VEGF options. Patients and doctors choose anti-VEGF therapies because they help protect eyesight and make vision clearer. New extended-release drug delivery methods will make these treatments easier to use and more effective which will drive market growth. As the market for anti-VEGF therapies expands, new competition and innovation in the sector will continue to drive growth in the retinal disorder treatment market.
- Shift Toward Minimally Invasive Treatment Options: More doctors now use minimally invasive treatments to help people with retinal diseases. People choose intravitreal injections and laser therapy plus micro-incision surgeries because these procedures help patients heal faster with lower risks and better treatment results. Experts now favor intravitreal anti-VEGF injections because they let medications reach the eye directly to fight diseases while causing fewer body-wide side effects. Research shows the market for minimally invasive medical procedures will expand further because patients want treatments that cause less harm and heal faster. New surgical methods including retinal microsurgery help doctors perform these treatments more effectively. The retinal disorder treatment market will grow quickly because patients prefer treatments that do not need many surgical steps.
- Integration of Digital Health in Retinal Disease Management: Digital healthcare solutions are now a main trend in treating retinal diseases. Digital healthcare technology helps doctors monitor and diagnose retinal disorders using telemedicine platforms and AI programs while mobile apps make patient care easier. Through image analysis AI systems help doctors find diseases earlier in patients with diabetic retinopathy and AMD. Through telemedicine patients in distant regions can talk to experts and get medical suggestions without extensive travel. The retinal disease treatment field will use digital health tools more due to market projections and healthcare provider technology adoption. These technologies help patients reach medical care better and make sure tests work correctly while tracking their medical conditions. Digital health solutions will boost market expansion especially in remote areas and developing nations because they support retinal disorder treatment.
- Current Advancements in Gene Therapy for Retinal Disorders: Scientists now consider gene therapy to be an efficient treatment for retinal disorders especially for patients with retinitis pigmentosa, Leber congenital amaurosis, and age-related macular degeneration. The tool of gene-editing like CRISPR also provides doctors with the expertise on treating diseases through fixing genetic problems. Researchers and doctors are making faster discoveries in retinal diseases through genetic research and clinical trials that test new gene therapies. As approved gene therapy products advance our medical system they can now help patients keep or regain their eyesight permanently. Pharmaceutical companies need to prioritize their investments in making precise gene treatments. Market expansion will accelerate because gene-based treatments open up fresh ways to handle retinal disorders while gene therapy availability grows rapidly. The number of patients who can access gene therapy treatment options will increase quickly because researchers now target more diseases while finding new therapeutic approaches worldwide. The ongoing research into personalized medicine and gene therapy is a critical driver for the expansion of retinal disorder treatment options.
- Growth of Anti-VEGF Therapy: Anti-VEGF treatment helps patients with AMD keep their vision because it is the standard medical practice to fight this eye disease in senior citizens. Doctors use anti-VEGF drugs like ranibizumab and aflibercept to stop blood vessels from developing abnormally in the retina which leads to wet AMD. The number of people affected by AMD is rising because more people are reaching older ages so treatments must keep up with this demand. Anti-VEGF treatments successfully stop wet AMD from worsening and help patients regain their vision. Healthcare providers now use these therapies regularly with patients. As medical experts continue studying this field they will develop better anti-VEGF therapies with stronger benefits and less side effects for longer periods. There is a profitable chance for companies developing anti-VEGF therapies because more people understand AMD and more of these treatments become available. Furthermore, the continued approval of anti-VEGF agents for other retinal conditions such as diabetic macular edema (DME) and retinal vein occlusion (RVO) is expected to further expand the market, offering new growth prospects in retinal disorder treatment.
- Increase in Patient Awareness and Early Diagnosis: The discovery of retinal diseases plus the need to find conditions early presents major growth chances for retinal disorder medicine companies. Medical imaging tools like optical coherence tomography (OCT) and retinal cameras help doctors find retinal problems sooner. Finding retinal problems early helps protect your eyesight above all else when it comes to diabetic retinopathy and age-related macular degeneration. More people get their eyes checked because of awareness programs which leads to finding retinal problems earlier. More patients need treatment for retinal disorders because early diagnosis has grown the patient population. Healthcare providers now have more chances to treat retinal disorders at early stages before they become permanent damage which creates new possibilities for market growth. Pharmaceutical companies can develop affordable diagnostic tests and treatments that help patients receive treatment earlier. The market grows because government authorities and non-profit organizations work together to teach people about retinal diseases. The market for retinal disorder treatments will grow because patients now have better chances of recovery when they receive treatment early.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Retinal Disorder Treatment Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Retinal Disorder Treatment Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Retinal Disorder Treatment Market is estimated to witness a CAGR of 9.11% from 2025 to 2031.
The major factors driving the Retinal Disorder Treatment Market are Increasing Prevalence of Retinal Disorders, Advancements in Retinal Disease Treatment Technologies, and Increased Focus on Early Detection and Diagnosis.
Future trends in the Retinal Disorder Treatment Market are Growing Use of Anti-VEGF Therapies, Development of Gene Therapies for Retinal Disorders, and Shift Toward Minimally Invasive Treatment Options.
Some of the players operating in the market are NOVARTIS AG, SANTEN PHARMACEUTICAL CO., LTD., REGENERON, GRAYBUG VISION, INC, SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED), BAYER AG, GENENTECH, INC., ACUCELA INC, PFIZER, INC, and OXURION NV.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Retinal Disorder Treatment Market - By Product Type
1.3.2 Retinal Disorder Treatment Market - By Disease Indication
1.3.3 Retinal Disorder Treatment Market - By Distribution Channel
1.3.4 Retinal Disorder Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RETINAL DISORDER TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RETINAL DISORDER TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. RETINAL DISORDER TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. RETINAL DISORDER TREATMENT - GLOBAL MARKET OVERVIEW
6.2. RETINAL DISORDER TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RETINAL DISORDER TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. GELS
7.3.1. Overview
7.3.2. Gels Market Forecast and Analysis
7.4. EYE SOLUTIONS
7.4.1. Overview
7.4.2. Eye Solutions Market Forecast and Analysis
7.5. CAPSULES AND TABLETS
7.5.1. Overview
7.5.2. Capsules and Tablets Market Forecast and Analysis
7.6. EYE DROPS
7.6.1. Overview
7.6.2. Eye drops Market Forecast and Analysis
7.7. OINTMENTS
7.7.1. Overview
7.7.2. Ointments Market Forecast and Analysis
8. RETINAL DISORDER TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. DIABETIC RETINOPATHY
8.3.1. Overview
8.3.2. Diabetic Retinopathy Market Forecast and Analysis
8.4. MACULAR DEGENERATION
8.4.1. Overview
8.4.2. Macular Degeneration Market Forecast and Analysis
8.5. DIABETIC MACULAR EDEMA
8.5.1. Overview
8.5.2. Diabetic Macular Edema Market Forecast and Analysis
8.6. RETINAL VEIN OCCLUSION
8.6.1. Overview
8.6.2. Retinal Vein Occlusion Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. RETINAL DISORDER TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. ONLINE PHARMACY
9.4.1. Overview
9.4.2. Online Pharmacy Market Forecast and Analysis
9.5. RETAIL PHARMACY
9.5.1. Overview
9.5.2. Retail Pharmacy Market Forecast and Analysis
10. RETINAL DISORDER TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Retinal Disorder Treatment Market Overview
10.1.2 North America Retinal Disorder Treatment Market Forecasts and Analysis
10.1.3 North America Retinal Disorder Treatment Market Forecasts and Analysis - By Product Type
10.1.4 North America Retinal Disorder Treatment Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Retinal Disorder Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Retinal Disorder Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Retinal Disorder Treatment Market
10.1.6.1.1 United States Retinal Disorder Treatment Market by Product Type
10.1.6.1.2 United States Retinal Disorder Treatment Market by Disease Indication
10.1.6.1.3 United States Retinal Disorder Treatment Market by Distribution Channel
10.1.6.2 Canada Retinal Disorder Treatment Market
10.1.6.2.1 Canada Retinal Disorder Treatment Market by Product Type
10.1.6.2.2 Canada Retinal Disorder Treatment Market by Disease Indication
10.1.6.2.3 Canada Retinal Disorder Treatment Market by Distribution Channel
10.1.6.3 Mexico Retinal Disorder Treatment Market
10.1.6.3.1 Mexico Retinal Disorder Treatment Market by Product Type
10.1.6.3.2 Mexico Retinal Disorder Treatment Market by Disease Indication
10.1.6.3.3 Mexico Retinal Disorder Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Retinal Disorder Treatment Market Overview
10.2.2 Europe Retinal Disorder Treatment Market Forecasts and Analysis
10.2.3 Europe Retinal Disorder Treatment Market Forecasts and Analysis - By Product Type
10.2.4 Europe Retinal Disorder Treatment Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Retinal Disorder Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Retinal Disorder Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Retinal Disorder Treatment Market
10.2.6.1.1 Germany Retinal Disorder Treatment Market by Product Type
10.2.6.1.2 Germany Retinal Disorder Treatment Market by Disease Indication
10.2.6.1.3 Germany Retinal Disorder Treatment Market by Distribution Channel
10.2.6.2 France Retinal Disorder Treatment Market
10.2.6.2.1 France Retinal Disorder Treatment Market by Product Type
10.2.6.2.2 France Retinal Disorder Treatment Market by Disease Indication
10.2.6.2.3 France Retinal Disorder Treatment Market by Distribution Channel
10.2.6.3 Italy Retinal Disorder Treatment Market
10.2.6.3.1 Italy Retinal Disorder Treatment Market by Product Type
10.2.6.3.2 Italy Retinal Disorder Treatment Market by Disease Indication
10.2.6.3.3 Italy Retinal Disorder Treatment Market by Distribution Channel
10.2.6.4 Spain Retinal Disorder Treatment Market
10.2.6.4.1 Spain Retinal Disorder Treatment Market by Product Type
10.2.6.4.2 Spain Retinal Disorder Treatment Market by Disease Indication
10.2.6.4.3 Spain Retinal Disorder Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Retinal Disorder Treatment Market
10.2.6.5.1 United Kingdom Retinal Disorder Treatment Market by Product Type
10.2.6.5.2 United Kingdom Retinal Disorder Treatment Market by Disease Indication
10.2.6.5.3 United Kingdom Retinal Disorder Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Retinal Disorder Treatment Market Overview
10.3.2 Asia-Pacific Retinal Disorder Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Retinal Disorder Treatment Market Forecasts and Analysis - By Product Type
10.3.4 Asia-Pacific Retinal Disorder Treatment Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Retinal Disorder Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Retinal Disorder Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Retinal Disorder Treatment Market
10.3.6.1.1 Australia Retinal Disorder Treatment Market by Product Type
10.3.6.1.2 Australia Retinal Disorder Treatment Market by Disease Indication
10.3.6.1.3 Australia Retinal Disorder Treatment Market by Distribution Channel
10.3.6.2 China Retinal Disorder Treatment Market
10.3.6.2.1 China Retinal Disorder Treatment Market by Product Type
10.3.6.2.2 China Retinal Disorder Treatment Market by Disease Indication
10.3.6.2.3 China Retinal Disorder Treatment Market by Distribution Channel
10.3.6.3 India Retinal Disorder Treatment Market
10.3.6.3.1 India Retinal Disorder Treatment Market by Product Type
10.3.6.3.2 India Retinal Disorder Treatment Market by Disease Indication
10.3.6.3.3 India Retinal Disorder Treatment Market by Distribution Channel
10.3.6.4 Japan Retinal Disorder Treatment Market
10.3.6.4.1 Japan Retinal Disorder Treatment Market by Product Type
10.3.6.4.2 Japan Retinal Disorder Treatment Market by Disease Indication
10.3.6.4.3 Japan Retinal Disorder Treatment Market by Distribution Channel
10.3.6.5 South Korea Retinal Disorder Treatment Market
10.3.6.5.1 South Korea Retinal Disorder Treatment Market by Product Type
10.3.6.5.2 South Korea Retinal Disorder Treatment Market by Disease Indication
10.3.6.5.3 South Korea Retinal Disorder Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Retinal Disorder Treatment Market Overview
10.4.2 Middle East and Africa Retinal Disorder Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Retinal Disorder Treatment Market Forecasts and Analysis - By Product Type
10.4.4 Middle East and Africa Retinal Disorder Treatment Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Retinal Disorder Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Retinal Disorder Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Retinal Disorder Treatment Market
10.4.6.1.1 South Africa Retinal Disorder Treatment Market by Product Type
10.4.6.1.2 South Africa Retinal Disorder Treatment Market by Disease Indication
10.4.6.1.3 South Africa Retinal Disorder Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Retinal Disorder Treatment Market
10.4.6.2.1 Saudi Arabia Retinal Disorder Treatment Market by Product Type
10.4.6.2.2 Saudi Arabia Retinal Disorder Treatment Market by Disease Indication
10.4.6.2.3 Saudi Arabia Retinal Disorder Treatment Market by Distribution Channel
10.4.6.3 U.A.E Retinal Disorder Treatment Market
10.4.6.3.1 U.A.E Retinal Disorder Treatment Market by Product Type
10.4.6.3.2 U.A.E Retinal Disorder Treatment Market by Disease Indication
10.4.6.3.3 U.A.E Retinal Disorder Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Retinal Disorder Treatment Market Overview
10.5.2 South and Central America Retinal Disorder Treatment Market Forecasts and Analysis
10.5.3 South and Central America Retinal Disorder Treatment Market Forecasts and Analysis - By Product Type
10.5.4 South and Central America Retinal Disorder Treatment Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Retinal Disorder Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Retinal Disorder Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Retinal Disorder Treatment Market
10.5.6.1.1 Brazil Retinal Disorder Treatment Market by Product Type
10.5.6.1.2 Brazil Retinal Disorder Treatment Market by Disease Indication
10.5.6.1.3 Brazil Retinal Disorder Treatment Market by Distribution Channel
10.5.6.2 Argentina Retinal Disorder Treatment Market
10.5.6.2.1 Argentina Retinal Disorder Treatment Market by Product Type
10.5.6.2.2 Argentina Retinal Disorder Treatment Market by Disease Indication
10.5.6.2.3 Argentina Retinal Disorder Treatment Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RETINAL DISORDER TREATMENT MARKET, KEY COMPANY PROFILES
12.1. NOVARTIS AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. SANTEN PHARMACEUTICAL CO., LTD.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. REGENERON
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GRAYBUG VISION, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED)
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BAYER AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. GENENTECH, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ACUCELA INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PFIZER, INC
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. OXURION NV.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. NOVARTIS AG2. SANTEN PHARMACEUTICAL CO., LTD.3. REGENERON4. GRAYBUG VISION, INC5. SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED)6. BAYER AG7. GENENTECH, INC.8. ACUCELA INC9. PFIZER, INC10. OXURION NV
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For